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Left Ventricular Systolic Performance Changes
in Mild Hypertensive Subjects Treated with
Antihypertensive Monotherapy or Placebo: The
Treatment of Mild Hypertension Study (TOMHS)
Should We Worry About the
Hypercholesterolemic Effects of
Anti-Hypertensive Medications?
Robert J. Bryg, David J. Bryg, Jon P. Schrage, Joseph P. Johns, William
F Graettinger. University ofNevada School ofMedicine and VAMC, Reno, NV
Several large studies have demonstrated improved morbidity and mortality
with lowering of blood pressure (BP) in hypertension IHTN). The drugs which
have been shown to lower BP and cardiovascular (CV) risk are beta blocking
agents and thiazide diuretics. In spite of the documented benefit from the
use of these agents, there is a tendency among some physicians to avoid
these two classes of drugs when treating HTN. One of the reasons quoted is
that both of these classes of drugs increase cholesterol levels, which is pos-
tulated to negate the CV risk reduction afforded by BP lowering. This study
was undertaken to determine the magnitude of benefit from the lowering
of BP with these drugs and compare it with the expected loss of benefit
due to increased cholesterol levels with these drugs. A decision analysis
was constructed utilizing a new life expectancy (LE) function. L1FESPANS
(Lagrange Interpolated Functions of Empirical Survival Percentages Approx-
imated by NEVADA Simulations) is designed to individualize mortality pre-
diction utilizing mortality data from the National Center for Health Statistics
and numerous large epidemiological studies. Modifiable factors which are
included in this model to assist in the survival prediction include: age, sex,
race, BR cholesterol level, current smoking history, and body mass index.
For the initial analysis, a 10% reduction in BP with a 5% increase in abso-
lute cholesterol level with these agents was assumed. Sensitivity analyses
were performed for a wide range of initial BPs, cholesterol levels and smok-
ing history. Reduction of BP with either of these agents resulted in 1-5 years
of additional LE depending on baseline conditions. Significant increases in
LE were predicted even in the elderly. A 5% rise in cholesterol, in contrast,
was associated with a 0.0-0.6 year decrease in LE. The reduction in LE for
increased cholesterol was at most 28% of the increase in LE due to BP lower-
ing. Women had a slightly greater reduction of LE from increased cholesterol
In conclusion, without taking the other metabolic effects of these agents into
consideration, the increase in CV risk due to the small predicted increase in
cholesterol only partially negates the benefits of BP lowering. These predic-
tions are based on studies utilizing high dose (50-100 mg) diuretics. Lower
doses will have even less effect on lipid profiles and the negative LE changes
in hypertensive patients.
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Glycogen Loading In Vivo Reverses Decreased
Function After Ischemic Preconditioning In Vitro
Population Prevalence of Wolff-Parkinson-White
Syndrome
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Torsten Doens!, Patrick Guthrie, Heinrich Taegtmeyer. Uni~ of Texas Houston
Medical School, Houston, TX
We recently observed that glycogen loading of the heart in vivo improves
ischemia tolerance to the same extent as ischemic preconditioning (IP). We
have now tested the hypothesis that glycogen loading is beneficial in a pro-
tocol where IP per se is not effective. We perfused hearts from fed animals
with bicarbonate buffer containing glucose (10 mM). Five min IP with 5 min
preconditioning-reperfusion (IP515) or 10 min normoxic perfusion (Control,
C) were preceded by a 15 min stabilization period and followed by 15 min
global. no flow ischemia witl 30 min of reperfusion. Glycogen loaded hearts
came from fasted animals, were perfused with buffer containing glucose
(10 mM). lactate (10 mM) and insulin (10 mU/ml) and were subjected to the
same protocol as IP515. Cardiac power and heart rate were assessed contin-
uously. Postischemic recovery was assessed by postischemic power as %
of preischemic power. Hearts were freeze-clamped for metabolites. Results:
Glycogen levels in vivo were higher in the glycogen loaded hearts than in C
1140 ± 4.5 vs. 70 ± 6.6 I-'mollg dry). IP515 did not improve postischemic re-
covery compared to C (68.5 ± 3.7% vs. 71.4 ± 3.5% of preischemic power,
n ~ 9 each). However, glycogen loading of this group resulted in a full re-
turn of cardiac power post ischemia (101 ± 6.1 %, n ~ 8). Levels of glucose-
6-phosphate IG-6-P), pyruvate, and lactate were not different in IP5/5 and C
and returned to preischemic levels with reperfusion. Glycogen loaded hearts
maintained elevated G-6-P and lactate levels with reperfusion. Conclusions:
Glycogen loading improves ischemia tolerance where IP fails to do so. Thus,
glycogen or glycogen breakdown may playa crucial role in myocardial pro-
tection.
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Little is known about the epidemiology of Wolff-Parkinson-White (WPW) syn-
drome in the general population. Virtually all previous studies have been ei-
ther case series from tertiary care centers or limited to young adult males
screened for military training. To date, there are no detailed studies of the
prevalence of WPW in the general population. To determine the prevalence
of WPW in the general population, we used the Marshfield Epidemiologic
Study Area (MESA). a population laboratory of 50,000 people residing in 12
contiguous zip codes in central Wisconsin. Prevalence was determined as
of 7/1/91 among MESA residents who had a diagnosis of WPW between
1/1/79 and 6/30/91. Cases were identified by reviewing the medical records
and electrocardiograms of: a) all 32 MESA residents with the WPW diagno-
sis identified by International Classification of Diseases, 9th Revision (ICD-9)
Code 426.7 as a hospital discharge or outpatient clinic diagnosis, b) 600 pa-
tients with suspected supraventricular arrhythmias identified by three ICD 9
codes, and c) all patients who had an invasive electrophysiology study for
overt WPW syndrome in our institution over the last 10 years.
Results: We identified 25 prevalent cases of WPW resulting in an overall
population prevalence of 5.1/10,000 (95% C.I, 3.1-7.1).
Age specific-prevalence rates per 10,000 were: 0-19 years - 2.0; 20-39
years - 5.5; 40-59 years - 9.6; >60 years - 4.8. There was no significant
difference in males versus females. Al125 verified cases were identified from
the 32 potential cases with ICD-9 Code 426,7, indicating that this code is
100% sensitive and has a 78% positive predictive value for WPW syndrome.
Conclusions: 1) The prevalence of WPW in the general population is lower
than that reported in selected populations and appears to be highest in those
of late middle-age. 2) Based on the findings of our study, we estimate that
there are approximately 130,000 individuals in the United States with elec-
trocardiographic documentation of WPW.
Philip Liebson, Greg Grandits, Ronald Prineas, Sinda Dianwmba, Richard Grimm.
Rush Medical College, Chicago, IL; University of Minnesota, Minneapolis, MN
Few large scale studies have evaluated long term effects of antihypertensive
monotherapy (MT) versus placebo (P) on left ventricular (LVI systolic perfor-
mance. Over a period of 4 years, 844 subjects with mild hypertension (mean
BP: 140/911 without cardiac disease were treated with one of 5 MTs or R all
receiving nutritional-hygienic intervention. 2-D directed M-mode echocardio-
grams evaluated LV function at baseline, 3 months and annually through 4
years. Average changes over4 years were compared between combined MT
groups and P. Average decrease in BP was 15.9/12.3 mmHg in the MT group
and 9.1/8.6 mmHg in the Pgroup. Forglobal systolic performance, stroke vol-
ume, ejection fraction, and fractional shortening (FS) increased with MT but
decreased in P (p < 0.01 (MT vs PI. Average change from baseline in stroke
volume was -3.0% with P and +1.7% with MT. Cardiac output, stroke work
index and minute work index decreased similarly in both MT and P. Peak-
and end-systolic stress (ESS) increased significantly more in P than MT Ip
< 0.01). Total peripheral resistance decreased more in the MT group (p <
0.001). For indexes of contractility, ESS/ES volume index increased more in
the P group, FS/ESS increased in MT and decreased in Rand SBP/ES dimen-
sion decreased more in the MT group (p < 0.02 for eachl.
These findings suggest that even in mild hypertensives without underlying
LV dysfunction, the addition of MT to nutritional-hygienic therapy can pro-
duce small, though significant changes in LV performance characteristics.
Effect of Hormone Replacement Therapy on
Fibrinogen Level in Postmenopausal Women in
the Framingham Offspring StUdy
Murray A. Mittleman, Otavio C.E. Gebara, Patrice Sutherland, Travis Matheney,
Izabela Lipinska, Francine K. Welty, Daniel Levy, Peter W.F Wilson, James E. Muller,
Geoffrey H. Tofler. Institute for Prevention of Cardiovascular Disease, Deaconess
Hospital, Harvard Medical School, and Framingham Heart StUdy, Boston, MA
Hormone replacement therapy (HRT) is associated with a decreased risk of
coronary heart disease (CHD) in postmenopausal women, but the mecha-
nism of its protective effect is not fully characterized. To evaluate the relation-
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Computerization of the Application of Parametric
Multivariable Risk Factor Analyses to Estimate
the Risk of Events After Cardiac Transplantation
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J. Jarcho, S. Kubo, F. Smart, Cardiac Transplant Research Database (CTRDI Group.
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The consideration of multivariable analysis derived risk factors for post trans-
plant events in the evaluation of potential cardiac transplant recipients and
donors may serve to improve mortality and morbidity after cardiac transplan-
tation. However, the application of this information is elusive due to the dif-
ficulty of applying all identified recipient and donor related risk factors, ex-
pressed as dichotomous and continuous variables, in the assessment of the
risk of post transplant events for a single patient. The CTRD has reported
multivariable risk factor analyses in the hazard function domain for post car-
diac transplant events from all primary transplants from 30 transplant centers
with 4.5 year follow-up. Variables analyzed in theses reports included multi-
ple recipient and donor demographic information, recipient and donor mis-
match variables, pre-transplant recipient and donor clinical variables, hemo-
dynamic variables, surgical variables, initial immunosuppression variables,
and post transplant event variables. Specific risk factors for post transplant
events were identified and multivariable equations were derived and have
been published,
In order to facilitate the application of this information, a computer pro-
gram was developed to allow the calculation of the estimated time-related
risk of post transplant events including death, time to first infection, time
to first rejection, and number of rejections in the first year. One enters the
values for specified variables into the program. The program then calculates
(utilizing solutions to the multivariable equations) and then displays the time-
related actuarial and hazard function curves, with standard errors, for each
event in graphical and tabular formats. Patient data may be stored, and data
output may be printed. Different patients or clinical situations for the same
patient may be compared on screen, The program is written in Microsoft
C, version 6, and runs in PC-DOS, Computer requirements include 640 kb
RAM, VGA graphics, and a floating point processor, Summary: Utilizing this
software package, a clinician may compute and print an individual patient's
time related risk profiles for post transplant death, infection, and allograft re-
jection. This information may be used for pre-transplant recipient education
and selection, and donor-recipient matching prior to transplantation.
William S. Weintraub, Fara Hicks, Debbie Canup, Peter Little, J, Larry Klein,
Ryan Gill, Candice Saunders, Douglas A. Morris, R. Wayne Alexander, Spencer
B, King III, Robert A, Guyton. Emory University School ofMedicine, Atlanta. GA
While information is crucial to medical care, organizing clinical and financial
data into useful, accessible information is difficult. Since 1972 Emory Uni-
versity has approached this with a clinical database (CDB) which includes
all cardiac catheterizations, coronary angioplasties and cardiac surgical pro-
cedures. Clinical data have been transcribed onto forms and hand keyed.
Financial data from the hospital and the Emory Clinic have been loaded via
tape. While the CDB has been used for clinical research, increasingly there
are demands to manage cardiovascular medicine on a daily basis. The com-
puter system was a traditional system with a central processor and terminals,
some of which had access via modem. This model has proven unworkable
due to 1) limited access geographically, 2) difficult access for personnel not
familial with with sophisticated database management system tools, 3} in-
creased expectations of what computers should do because of exposure to
graphical user interfaces (GUls) on personal computers, 4) inabilityto extend
data collection into new areas via paper forms and 5) increased demands
for service as a daily management tool. Independently of this effort Emory
University has put into place an Enterprise network, In 1993 the CDB, on a
Unix server, was made available on the network. Access is now available via
any IBM PC or compatible or Macintosh on the network. Access for both
individual and group data is being continually upgraded and simplified us-
ing GUI approaches, Local databases in cardiothoracic surgery and cardiac
Distributing a Cardiology Database on an
Enterprise Network: Changing Paradigms in
Information Systems
with significant CAD based on non-invasive data. We trained the ANN by us-
ing non-invasive data from 276 consecutive patients who underwent cardiac
catheterization, Input data included age, sex, history, physical exam, cardiac
risk factors, exercise stress test data (with or without nuclear imaging), The
ANN was trained to recognize significant CAD, defined as > 50% obstruc-
tion of the left main or other major epicardial vessels, The ANN was then
applied to patients not used in training. Significant CAD was identified with
a positive predictive accuracy of 80%, and a negative predictive accuracy of
92%. In conclusion, ANN can exclude patients without significant CAD with
a high degree (92%) of confidence. This technique has the potential to limit
the use of costly invasive procedures,
<0.001'
<0.001"
p-value
10.3 ± 1.8
8.8 ± 1.8
7.8 ± 18
t7.7%*
t9,3%**
%D.
tPA antigen lng/mil
basal 9 weeks
10.3±1.8
9.9 ± 18
9.8± 18
Fibrinogen Img/dll
289 ± 53
313 ± 58
284 ± 44
56 ± 8
62 ± 8
85 ± 8
Fibrinolytic Potential is Increased by Estrogen
Therapy in Postmenopausal Women
Fibrinolytic activity (mm2)
basal 9 weeks
Artificial Neural Networks Can Predict
Significant Coronary Disease
46 ± 8
50 ± 8
48 ± 8
N
Premenopause 303
Postmenopause (No HRT) 383
Postmenopause (HRT) 86
'Premenopause vs. Postmenopause (No HRT);
"Postmenopause (No HRT) vS. Postmenopause (HRT) (Age adjusted)
'p < 0.05, basal vs 9 weeks
1998-1221
Placebo
Estraceill 1 rng
Estrace iS 2 rng
ship between postmenopausal HRT and fibrinogen, an established hemo-
static risk factor for CHD, we measured fibrinogen using the Clauss method
in 858 women free of CHD in cycle 4 of the Framingham Offspring Study.
The table shows mean ± SD fibrinogen levels for pre and postmeonopausal
women according to use of HRl
Dipti Itchhaporia, Robert Almassy, Louis Kaufman, Peter Snow, William Oetgen.
Georgetown University, Washington, D.c.; Kaman Sciences Corpora~'on, Colorado
Springs. CO
In the era of health care reform, third party health payors are using deci-
sion support systems to justify the use of costly invasive procedures. In
the field of cardiology, a technology that could predict significant coronary
artery disease (CAD) from non-invasive data would be helpful. Artificial neu-
ral networks (ANN) have the potential to recognize subtle patterns in data
and apply its training to a new set of data. We trained a personal computer-
based ANN, using back propagation of errors through 23 hidden neurons,
incorporating logistic transfer function, in a single layer, to identify patients
These differences persisted upon multivariate adjustment for smoking,
use of antihypertensive medication, diabetes mellitus, body mass index, al-
cohol intake, total cholesterol and HDL cholesterol.
Postmenopausal HRT is associated with fibrinogen levels that are com-
parable to those found in premenopausal women. These data suggest that
the protective effect of postmenopausal HRT may be mediated in part by
favorable alterations in the hemostatic system.
Otavio C.E. Gebara, Brian Walsh, Murray A, Mittleman, Louise Greenberg, Francine
K, Welty, Izabela Lipinska, Da-Li Feng, Frank Sacks, Geoffrey H. Tofler, Institute for
Prevention of Cardiovascular Disease, Deaconess Hospital, and Brigham and Women's
Hospital, Harvard Medical School, Boston, MA
Estrogen usage in postmenopausal women is associated with a decrease in
cardiovascular events, however the mechanism is not well characterized. Al-
though observational studies suggest that estrogen may act in part through
an improvement in fibrinolytic potential, this has not been established in
placebo-controlled trials before and after estrogen therapy.
We performed a randomized, double-blind, placebo-controlled crossover
trial of oral estradiol (Estrace®, 1 mg, 2 mg) in 20 postmenopausal women.
Samples for fibrinolytic activity (fibrin plate assay) and tissue type plasmino-
gen activator (t-PAj antigen were collected at baseline and after 3, 6 and
9 weeks of therapy. Elevated t-PA antigen levels are associated with in-
creased cardiovascular risk, A repeated measures analysis of variance was
performed. There were significant treatment effects on fibrinolytic activity
and t-PA antigen. Results are presented for basal and 9 week timepoints.
Fibrinolytic potential is increased by estrace therapy, as indicated by an
increase in fibrinolytic activity and a reduction in tPA antigen. The effect was
more marked with the 2 mg preparation.
Since increased fibrinolytic activity has been associated with reduced car-
diovascular risk, these data suggest that one mechanism of the risk reduc-
tion associated with estrogen therapy in postmenopausal women may be
via a reduction in thrombotic tendency,
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